Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Sales

Avricore Health (AVCRF) EBITDA Margin (2016 - 2025)

Avricore Health has reported EBITDA Margin over the past 11 years, most recently at 1351.21% for Q4 2025.

  • Quarterly EBITDA Margin fell 135764.0% to 1351.21% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 263.01% through Dec 2025, down 26584.0% year-over-year, with the annual reading at 259.13% for FY2025, 26183.0% down from the prior year.
  • EBITDA Margin was 1351.21% for Q4 2025 at Avricore Health, down from 1005.97% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 9442.98% in Q1 2021 and troughed at 1602.16% in Q2 2025.
  • The 5-year median for EBITDA Margin is 4.96% (2023), against an average of 691.8%.
  • Year-over-year, EBITDA Margin soared 980858bps in 2021 and then tumbled -900851bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 593.62% in 2021, then tumbled by -104bps to 24.43% in 2022, then soared by 121bps to 5.07% in 2023, then grew by 27bps to 6.44% in 2024, then crashed by -21096bps to 1351.21% in 2025.
  • Per Business Quant, the three most recent readings for AVCRF's EBITDA Margin are 1351.21% (Q4 2025), 1005.97% (Q3 2025), and 1602.16% (Q2 2025).